A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia with Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Nelotanserin (Primary)
- Indications Dementia; Lewy body disease; Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Axovant Sciences
- 13 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.
- 13 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Aug 2018.
- 13 Feb 2018 Status changed from recruiting to active, no longer recruiting.